Scholarlink

Background <p>For more than 30&#xa0;years, the St. Gallen (SG) International Consensus Conference on the treatment of patients with primary breast cancer (SGBCC) has been taking place regularly. The SGBCC consensus is based on the majority vote of the SG panel and represents an international cross-section of opinions.</p> Rationale <p>This article discusses and classifies the panel members’ voting results for everyday clinical practice in Germany.</p> Basis <p>The discussion is based on the German treatment recommendations of the ‘Arbeitsgemeinschaft Gynäkologische Onkologie’ (AGO Organkommission Mamma, Version 2025.1) which is updated every year, most recently in March 2025. The updated S3 guideline on ‘Early detection, diagnosis, therapy and follow-up of breast cancer’ was only available as a&#xa0;consultation version at the time.</p> Results <p>This year’s 19th&#xa0;SGBCC focused on practice-oriented issues related to early breast cancer, which—in part—were discussed and agreed upon using fictitious case studies with different variables. The rationale behind this was to address the increasingly personalized treatment decisions for early breast cancer. More than ever, not only tumor stage, tumor biology, breast cancer subtype, performance status, age or life expectancy are considered as individual factors, but also various molecular and genetic variables are part of the treatment decision-making process. The present manuscript is focusing on systemic tumor therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medikamentöse Therapie des frühen Mammakarzinoms

  • 期刊论文

  • 发表日期：

    2025年12月10日

查看全文
  • Diana Lüftner,
  • Maggie Banys-Paluchowski,
  • Sara Y. Brucker,
  • Carsten Denkert,
  • Nina Ditsch,
  • Peter A. Fasching,
  • Renate Haidinger,
  • Nadia Harbeck,
  • Jens Huober,
  • Wolfgang Janni,
  • David Krug,
  • Sibylle Loibl,
  • Laura Michel,
  • Eva Schumacher-Wulf,
  • Christine Solbach,
  • Michael Untch,
  • Rachel Würstlein,
  • Harold Burstein,
  • Vorsitz Stephan Aebi,
  • Meteb Al-Foheidi,
  • Zsuzsanna Bago-Horvath,
  • Francois-Clément Bidard,
  • Judy Boughey,
  • Denisse Bretel Morales,
  • Sara Y. Brucker,
  • Harold J. Burstein,
  • Maria Joao Cardoso,
  • Lisa Carey,
  • Steven Chia,
  • Charlotte Coles,
  • Javier Cortes,
  • Giuseppe Curigliano,
  • Shaheena Dawood,
  • Jana de Boniface,
  • Angela De,
  • Michele,
  • Carsten Denkert,
  • Gerd Fastner,
  • Prudence Francis,
  • Viviana Enrica Galimberti,
  • Heba Gamal,
  • Armando Giuliano,
  • Michael Gnant,
  • Bahadir Gulluoglu,
  • Nadia Harbeck,
  • Chiun-Sheng Huang,
  • Jens Huober,
  • Wolfgang Janni,
  • Komal Jhaveri,
  • Zefei Jiang,
  • China Orit Kaidar-Person,
  • Virginia Kaklamani,
  • Kevin Kalinsky,
  • Daniela Kauer-Dorner,
  • Catherine M. Kelly,
  • Sung Yong Kim,
  • Marleen Kok,
  • Matteo Lambertini,
  • Sherene Loi,
  • Sibylle Loibl,
  • Terry Mamounas,
  • Kelly Metcalfe,
  • Laura Michel,
  • Monica Morrow,
  • Anusheel Munshi,
  • Mafalda Oliveira,
  • Shani Paluch-Shimon,
  • Martine Piccart,
  • Shelley Potter,
  • Meredith Regan,
  • Isabel Rubio,
  • Hope S. Rugo,
  • Shigehira Saji,
  • Cristina Saura Manic,
  • Elzbieta Senkus-Konefka,
  • Zhiming Shao,
  • Christian Singer,
  • Christine Solbach,
  • Christoph Tausch,
  • Beat Thürlimann,
  • Eriko Tokunaga,
  • Nicholas Turner,
  • Andrew Tutt,
  • Cicero Urban,
  • Marcus Vetter,
  • Cynthia Villarreal-Garza,
  • Marie-Jeanne Vranken-Peeters,
  • Walter Weber,
  • Hans Wildiers,
  • Fraser Symmans William,
  • Binghe Xu,
  • Yongmei Yin,
  • Harold Burstein,
  • David Cameron,
  • Giuseppe Curigliano,
  • Carsten Denkert,
  • Michael Gnant,
  • Sherene Loi,
  • Sibylle Loibl,
  • Philip Poortmans,
  • Meredith Regan,
  • Beat Thürlimann,
  • Walter Weber

摘要

Background

For more than 30 years, the St. Gallen (SG) International Consensus Conference on the treatment of patients with primary breast cancer (SGBCC) has been taking place regularly. The SGBCC consensus is based on the majority vote of the SG panel and represents an international cross-section of opinions.

Rationale

This article discusses and classifies the panel members’ voting results for everyday clinical practice in Germany.

Basis

The discussion is based on the German treatment recommendations of the ‘Arbeitsgemeinschaft Gynäkologische Onkologie’ (AGO Organkommission Mamma, Version 2025.1) which is updated every year, most recently in March 2025. The updated S3 guideline on ‘Early detection, diagnosis, therapy and follow-up of breast cancer’ was only available as a consultation version at the time.

Results

This year’s 19th SGBCC focused on practice-oriented issues related to early breast cancer, which—in part—were discussed and agreed upon using fictitious case studies with different variables. The rationale behind this was to address the increasingly personalized treatment decisions for early breast cancer. More than ever, not only tumor stage, tumor biology, breast cancer subtype, performance status, age or life expectancy are considered as individual factors, but also various molecular and genetic variables are part of the treatment decision-making process. The present manuscript is focusing on systemic tumor therapy.